Alpha Emitter Market Size to Surpass USD 1,488.02 Mn By 2033

The global Alpha emitter market size was estimated to be around US$ 581.6 million in 2023 and is projected to reach US$ v, indicating a CAGR of 9.90% from 2024 to 2033.

Key Takeaways

• North America contributed more than 44% of market share in 2023.
• Asia-Pacific is estimated to expand at the fastest CAGR between 2024 and 2033.
• By type of radionuclide, the actinium (Ac-225) segment has held the largest market share of 38% in 2023.
• By type of radionuclide, the radium (Ra-223) segment is anticipated to grow at a remarkable CAGR of 10.16% between 2024 and 2033.
• By application, the bone metastases segment generated over 36% of the market share in 2023.
• By application, the prostate cancer segment is expected to expand at the fastest CAGR over the projected period.
• By source, the natural sources segment generated over 54% of the market share in 2023.
• By source, the artificially produced sources segment is expected to expand at the fastest CAGR over the projected period.

The Alpha Emitter Market is a dynamic sector characterized by the growing demand for alpha emitters in various industrial applications. Alpha emitters, radioactive substances emitting alpha particles, have gained prominence due to their use in medical treatments, industrial processes, and scientific research. The market is witnessing steady growth driven by advancements in technology and an expanding range of applications.

Get a Sample: https://www.precedenceresearch.com/sample/3690

Growth Factors

Several factors contribute to the positive growth trajectory of the Alpha Emitter Market. The increasing prevalence of cancer and the rising adoption of alpha-emitting radionuclides in targeted alpha-particle radiotherapy are major growth drivers. Additionally, advancements in nuclear medicine and radiopharmaceuticals have opened new avenues for alpha emitters. The expanding scope of applications, including environmental monitoring and nuclear power generation, further fuels market growth.

Alpha Emitter Market Scope

Read More: Metaverse in E-commerce Market Size to Worth USD 936.28 Bn By 2033

Opportunities

The Alpha Emitter Market presents promising opportunities for innovation and expansion. Ongoing research and development activities in nuclear medicine create possibilities for the discovery of novel alpha-emitting radionuclides with enhanced therapeutic properties. Furthermore, collaborations between pharmaceutical companies and research institutions offer avenues for the development of cutting-edge alpha emitter-based therapies. Market players can capitalize on these opportunities to strengthen their market presence.

Challenges

Despite the positive outlook, the Alpha Emitter Market faces certain challenges that require strategic consideration. Regulatory complexities surrounding the use of radioactive materials pose hurdles for market players. Additionally, concerns related to radiation safety and waste management present challenges for widespread adoption. Mitigating these challenges necessitates a proactive approach, including compliance with stringent regulations and the development of efficient waste disposal mechanisms.

Reasons to Purchase this Report:

• Comprehensive market segmentation analysis incorporating qualitative and quantitative research, considering the impact of economic and policy factors.
• In-depth regional and country-level analysis, examining the demand and supply dynamics that influence market growth.
• Market size in USD million and volume in million units provided for each segment and sub-segment.
• Detailed competitive landscape, including market share of major players, recent projects, and strategies implemented over the past five years.
• Comprehensive company profiles encompassing product offerings, key financial information, recent developments, SWOT analysis, and employed strategies by major market players.

Alpha Emitter Market Companies

• Alpha Tau Medical Ltd.
• NorthStar Medical Radioisotopes
• IBA Worldwide
• RadioMedix
• Orano Med
• Bayer AG
• Novartis International AG
• Actinium Pharmaceuticals, Inc.
• Fusion Pharmaceuticals Inc.
• Eckert & Ziegler
• Telix Pharmaceuticals Limited
• Curium Pharma
• AAA (Advanced Accelerator Applications)
• Isotopen Technologien München AG (ITM)
• Nordion (Canada) Inc.

Segments Covered in the Report

By Type of Radionuclide

• Radium (Ra-223)
• Actinium (Ac-225)
• Lead (Pb-212)
• Astatine-211
• Bismuth-213
• Others

By Application

• Bone Metastases
• Prostate Cancer
• Neuroendocrine Tumors
• Ovarian Cancer
• Others

By Source

• Natural Sources (Uranium-238, Radium-226)
• Artificially Produced Sources (Plutonium, Americium, Curium, Californium)
• Others

By Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Alpha Emitter Market 

5.1. COVID-19 Landscape: Alpha Emitter Industry Impact

5.2. COVID 19 – Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Alpha Emitter Market, By Type of Radionuclide

8.1. Alpha Emitter Market, by Type of Radionuclide, 2024-2033

8.1.1 Radium (Ra-223)

8.1.1.1. Market Revenue and Forecast (2021-2033)

8.1.2. Actinium (Ac-225)

8.1.2.1. Market Revenue and Forecast (2021-2033)

8.1.3. Lead (Pb-212)

8.1.3.1. Market Revenue and Forecast (2021-2033)

8.1.4. Astatine-211

8.1.4.1. Market Revenue and Forecast (2021-2033)

8.1.5. Bismuth-213

8.1.5.1. Market Revenue and Forecast (2021-2033)

8.1.6. Others

8.1.6.1. Market Revenue and Forecast (2021-2033)

Chapter 9. Global Alpha Emitter Market, By Application

9.1. Alpha Emitter Market, by Application, 2024-2033

9.1.1. Bone Metastases

9.1.1.1. Market Revenue and Forecast (2021-2033)

9.1.2. Prostate Cancer

9.1.2.1. Market Revenue and Forecast (2021-2033)

9.1.3. Neuroendocrine Tumors

9.1.3.1. Market Revenue and Forecast (2021-2033)

9.1.4. Ovarian Cancer

9.1.4.1. Market Revenue and Forecast (2021-2033)

9.1.5. Others

9.1.5.1. Market Revenue and Forecast (2021-2033)

Chapter 10. Global Alpha Emitter Market, By Source 

10.1. Alpha Emitter Market, by Source, 2024-2033

10.1.1. Natural Sources (Uranium-238, Radium-226)

10.1.1.1. Market Revenue and Forecast (2021-2033)

10.1.2. Artificially Produced Sources (Plutonium, Americium, Curium, Californium)

10.1.2.1. Market Revenue and Forecast (2021-2033)

10.1.3. Others

10.1.3.1. Market Revenue and Forecast (2021-2033)

Chapter 11. Global Alpha Emitter Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)

11.1.2. Market Revenue and Forecast, by Application (2021-2033)

11.1.3. Market Revenue and Forecast, by Source (2021-2033)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)

11.1.4.2. Market Revenue and Forecast, by Application (2021-2033)

11.1.4.3. Market Revenue and Forecast, by Source (2021-2033)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)

11.1.5.2. Market Revenue and Forecast, by Application (2021-2033)

11.1.5.3. Market Revenue and Forecast, by Source (2021-2033)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)

11.2.2. Market Revenue and Forecast, by Application (2021-2033)

11.2.3. Market Revenue and Forecast, by Source (2021-2033)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)

11.2.4.2. Market Revenue and Forecast, by Application (2021-2033)

11.2.4.3. Market Revenue and Forecast, by Source (2021-2033)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)

11.2.5.2. Market Revenue and Forecast, by Application (2021-2033)

11.2.5.3. Market Revenue and Forecast, by Source (2021-2033)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)

11.2.6.2. Market Revenue and Forecast, by Application (2021-2033)

11.2.6.3. Market Revenue and Forecast, by Source (2021-2033)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)

11.2.7.2. Market Revenue and Forecast, by Application (2021-2033)

11.2.7.3. Market Revenue and Forecast, by Source (2021-2033)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)

11.3.2. Market Revenue and Forecast, by Application (2021-2033)

11.3.3. Market Revenue and Forecast, by Source (2021-2033)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)

11.3.4.2. Market Revenue and Forecast, by Application (2021-2033)

11.3.4.3. Market Revenue and Forecast, by Source (2021-2033)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)

11.3.5.2. Market Revenue and Forecast, by Application (2021-2033)

11.3.5.3. Market Revenue and Forecast, by Source (2021-2033)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)

11.3.6.2. Market Revenue and Forecast, by Application (2021-2033)

11.3.6.3. Market Revenue and Forecast, by Source (2021-2033)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)

11.3.7.2. Market Revenue and Forecast, by Application (2021-2033)

11.3.7.3. Market Revenue and Forecast, by Source (2021-2033)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)

11.4.2. Market Revenue and Forecast, by Application (2021-2033)

11.4.3. Market Revenue and Forecast, by Source (2021-2033)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)

11.4.4.2. Market Revenue and Forecast, by Application (2021-2033)

11.4.4.3. Market Revenue and Forecast, by Source (2021-2033)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)

11.4.5.2. Market Revenue and Forecast, by Application (2021-2033)

11.4.5.3. Market Revenue and Forecast, by Source (2021-2033)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)

11.4.6.2. Market Revenue and Forecast, by Application (2021-2033)

11.4.6.3. Market Revenue and Forecast, by Source (2021-2033)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)

11.4.7.2. Market Revenue and Forecast, by Application (2021-2033)

11.4.7.3. Market Revenue and Forecast, by Source (2021-2033)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)

11.5.2. Market Revenue and Forecast, by Application (2021-2033)

11.5.3. Market Revenue and Forecast, by Source (2021-2033)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)

11.5.4.2. Market Revenue and Forecast, by Application (2021-2033)

11.5.4.3. Market Revenue and Forecast, by Source (2021-2033)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Type of Radionuclide (2021-2033)

11.5.5.2. Market Revenue and Forecast, by Application (2021-2033)

11.5.5.3. Market Revenue and Forecast, by Source (2021-2033)

Chapter 12. Company Profiles

12.1. Alpha Tau Medical Ltd.

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. NorthStar Medical Radioisotopes

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. IBA Worldwide

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. RadioMedix

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Orano Med

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Bayer AG

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Novartis International AG

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Actinium Pharmaceuticals, Inc.

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Fusion Pharmaceuticals Inc.

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Eckert & Ziegler

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: sales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Blog: https://www.expresswebwire.com/

Blog: https://www.uswebwire.com/

Blog: https://www.dailytechbulletin.com/

Blog: https://www.autoindustrybulletin.com/